Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma - Results of a randomized, double-blind, placebo-controlled trial
Autore:
Black, CM; Silman, AJ; Herrick, AI; Denton, CP; Wilson, H; Newman, J; Pompon, L; Xu, SW;
Indirizzi:
RoyalNW3ee Hosp, Royal Free Acad Unit Rheumatol & Connect Tissue D, LondonRoyal Free Hosp London England NW3 2QG umatol & Connect Tissue D, London Univ Manchester, Manchester, Lancs, England Univ Manchester Manchester Lancs England ter, Manchester, Lancs, England Univ Manchester, Hope Hosp, Salford M6 8HD, Lancs, England Univ Manchester Salford Lancs England M6 8HD lford M6 8HD, Lancs, England
Titolo Testata:
ARTHRITIS AND RHEUMATISM
fascicolo: 2, volume: 42, anno: 1999,
pagine: 299 - 305
SICI:
0004-3591(199902)42:2<299:IDNIOA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYSTEMIC-SCLEROSIS; MULTICENTER TRIAL; CLINICAL-TRIALS; GAMMA; FIBROBLASTS; COLLAGEN; EXPRESSION; FIBROSIS; SKIN;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Black, CM Royal,Free Hosp, Royal Free Acad Unit Rheumatol & Connect TissueD, Pond St Royal Free Hosp Pond St London England NW3 2QG issue D, Pond St
Citazione:
C.M. Black et al., "Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma - Results of a randomized, double-blind, placebo-controlled trial", ARTH RHEUM, 42(2), 1999, pp. 299-305

Abstract

Objective, To determine whether interferon-alpha (IFN alpha) reduces the severity of skin involvement in early (<3 years) diffuse scleroderma. Methods. In a randomized, placebo-controlled, double-blind trial, 35 patients with early scleroderma received subcutaneous injections of either IFN alpha (13.5 x 106 units per week in divided doses) or indistinguishable placebo. Outcomes assessed were the modified Rodnan skin score, as determined by a single observer at baseline, 6 months, and 12 months, as well as data on renal, cardiac, and lung function. Pre- and posttreatment skin biopsy samples were analyzed and blood was obtained for assessment of procollagen peptide levels. Results. There were 11 withdrawals from the IFN alpha group and 3 from theplacebo group due to either toxicity, lack of efficacy, or death. In the intent-to-treat analysis, there was a greater improvement in the skin score in the placebo group between 0 and 12 months (mean change IFN alpha -4.7 versus placebo -7.5; P = 0.36). There was also a greater deterioration in lung function in patients receiving active therapy, as assessed by either the forced vital capacity (mean change IFN alpha -8.2 versus placebo +1.3; P = 0.01) or the diffusing capacity for carbon monoxide (mean change IFN alpha -9.3 versus placebo +4.7; P = 0.002). Skin biopsy showed no significant decrease in collagen synthesis in the IFN alpha group, and no significant differences in the levels of procollagen peptides were seen between the 2 groups. Conclusion. This study suggests that IFN alpha is of no value in the treatment of scleroderma, and that it may in fact be deleterious.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 05:36:42